Close Menu

Breaking News

The company will use the money to acquire PCR equipment to be used in connection with sales of reagents for infectious disease tests, among other uses.

The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 63 percent year over year.

Qiagen, which is also developing a single-plex qRT-PCR assay for SARS-CoV-2, said it will have a syndromic panel including targets for the virus ready this month.

Researchers sequenced about 200 mumps cases from Massachusetts and elsewhere to understand how the virus spread locally and more broadly in 2016 and 2017.

Based on expression patterns in mouse strains with variable infection susceptibility, investigators came up with a signature that predicted Ebola virus response in West Africa patients.

The firm will apply the funds to development of a next generation of its digital PCR system as well as expansion in Asia.

The GenFlex is a sample-to-result molecular diagnostic platform that includes sample collection, processing, amplification, and detection, the company said.

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

Extending a prior agreement with the drugmaker, Personalis will use its DNA/RNA platform to identify both predictive biomarkers and resistance mechanisms.

The company filed the application based on the PAOLA-1 data, which showed HRD-positive ovarian cancer patients saw pronounced benefit from the combo.

The new Series B investment was made by Northpond Ventures, with previously invested $20 million in the Australian diagnostics company.

Vienna-based Aelian combines CRISPR-Cas9 screening techniques with single-cell sequencing to identify and investigate disease targets and drug mechanisms of action.

The firm submitted its Verigene II Gastrointestinal Flex Assay to the FDA in Q4 and expects to submit Verigene II Respiratory Flex Assay to the agency in Q1 2020.

Fourth quarter revenues of $32.4 million were in line with previously reported preliminary revenues and ahead of the Wall Street estimate of $30.8 million.

Chinese researchers conducted a systematic comparison between the newly discovered coronavirus genome and SARS-like viruses that caused previous epidemics.

The president's latest budget request marks the fourth time he has sought to reduce funding to the National Institutes of Health.

The EPO rejected arguments that were filed in opposition to the patent, which covers the use of CRISPR-Cas9 in cellular and non-cellular settings.

Last week, GenomeWeb's readers were most interested in a court ruling on the patent infringement lawsuit between Illumina and BGI.

The Seoul-based firm said its PCR-based test kit is the first novel coronavirus assay to be granted emergency use authorization in Korea.

Pages

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.